Refractory chronic graft-versus-host disease (cGVHD) is a significant complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). Mesenchymal stromal cells (MSCs) have shown promise for treating refractory cGVHD, but the favorable effects of MSCs therapy in cGVHD are complex and not fully understood. In this prospective clinical study, 20 of 23 cGVHD patients had a complete response or partial response in a 12-month follow-up study. The most marked improvements in cGVHD symptoms were observed in the skin, oral mucosa and liver. Clinical improvement was accompanied by a significantly increased number of interleukin (IL)-10-producing CD5+ B cells. Importantly, CD5+ B cells from cGVHD patients showed increased IL-10 expression after MSCs treatment, which was associated with reduced inflammatory cytokine production by T cells. Mechanistically, MSCs could promote the survival and proliferation of CD5+ regulatory B cells (Bregs), and indoleamine 2, 3-dioxygenase partially participates in the MSC-mediated effects on Breg cells. Thus, CD5+ Breg cells may have an important role in the process of MSC-induced amelioration of refractory cGVHD and may provide new clues to reveal novel mechanisms of action for MSCs.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for malignant diseases of the hematopoietic and immune systems. However, the development of graft-versushost disease (GVHD) after HSC transplantation limits the wider application of this therapy. Over the past several years, chronic GVHD (cGVHD) has emerged as the most troublesome complication of allogeneic HSCT. 1 Although the administration of glucocorticoids with or without calcineurin inhibitors remains the standard initial treatment, the existence of significant side effects and unsatisfactory outcomes supports the need for more effective and less toxic new therapies. 2 Mesenchymal stromal cells (MSCs) are multipotent progenitor cells that can be isolated from various adult tissues. 3 In addition to their self-renewal capacity and multipotency, 3, 4 MSCs also have potent immunomodulatory effects on both innate and adaptive immune cells. [5] [6] [7] [8] [9] Their success has been demonstrated in preclinical and clinical therapies for a variety of inflammatory and autoimmune diseases; 10, 11 they have also been shown to prolong graft survival in several animal models of solid organ transplantation 12, 13 and to effectively control lethal murine GVHD. 14 These exciting results implied that MSCs may also be a potential therapeutic agent for cGVHD, which is the major reason for late morbidity and mortality after allogeneic HSCT and which has no current satisfactory treatment. One report has suggested that MSCs could ameliorate sclerodermatous cGVHD. 15 Recently, our group demonstrated that MSCs treatment may be a safe and effective salvage therapy for patients with steroid-resistant cGVHD. 16 Although previous studies using in vitro assays and animal models have demonstrated that MSCs can inhibit the proliferation and function of major immune cells, the immune effectors change after MSCs treatment, and the therapeutic mechanisms by which MSCs ameliorate cGVHD in patients remain unclear.
B cells have increasingly been recognized in recent years as major factors in cGVHD; 17 certain subsets of B cells, such as regulatory CD5+ B cells, may also have a protective function by maintaining peripheral tolerance, secreting interleukin-10 (IL- 10) or inducing the differentiation of T regulatory cells. [18] [19] [20] [21] [22] cGVHD is distinct from acute GVHD (aGVHD) and resembles autoimmune disease. 23 CD5+ B cells have been shown to be involved in the protection from autoimmunity by the production of cytokines such as IL-10. [19] [20] [21] [22] 24 After HSCT, patients with cGVHD have an obviously impaired reconstitution of CD5+ B cells. 25, 26 Here, we investigate the role of CD5+ B cells in the MSCs treatment of refractory cGVHD patients.
MATERIALS AND METHODS

Study design
Commencing in June 2009, a total of 23 refractory cGVHD patients were enrolled in this study. Eligible patients had classic cGVHD symptoms without the features of either aGVHD or an overlapping syndrome, defined by the presence of at least one diagnostic or distinctive manifestation of cGVHD confirmed by pertinent biopsy according to the National Institutes of Health consensus criteria. 27 Refractory cGVHD was defined as disease in patients who were resistant or refractory to therapy with corticosteroids (equivalent of prednisone ⩾ 0.5 mg/kg per day or 1 mg/kg every other day) for 30 days at any time within the previous 12 months and who were on stable doses of other immunosuppressive medications (for example, calcineurin inhibitors with or without mycophenolate mofetil). 28 The clinical characteristics of all patients are summarized in Table 1 .
All enrolled patients received three infusions of MSCs derived from thirdparty healthy donors in addition to the original immunosuppressive therapy (the isolation and characterization of the MSCs are described in the Supplementary Information, Supplementary Figures S1 and S2 ). The dose of MSCs was 1 × 10 6 cells/kg per infusion; three doses were given at 4-week intervals. Follow-up was conducted monthly for the first trimester and every 3 months thereafter until 12 months.
The NIH consensus criteria and cGVHD score 29 were used for the cGVHD diagnosis, organ scoring and global assessment of the cGVHD status before the MSCs treatment and at each follow-up visit, as described in the Supplementary Information.
This prospective pilot study was performed in accordance with the tenets of the modified Helsinki Declaration, and the protocol was approved by the relevant Ethics Review Board before initiation. All recipients and/or guardians and all donors provided written informed consent.
Processing of peripheral blood cells and plasma
Heparinized peripheral blood was obtained from non-GVHD patients and from patients with cGVHD before MSCs treatment and 3 and 12 months after the first MSCs infusion. Plasma was separated from whole-blood cells by centrifugation, and peripheral blood mononuclear cells were isolated by centrifugation using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, GE Healthcare, Uppsala, Sweden) and stored in aliquots in liquid nitrogen.
Quantitative reverse transcription-PCR analyses
Using a commercial kit (Roche, New York, NY, USA), total RNA was extracted from CD5+ B cells in cGVHD patients both before and after the MSCs treatment. Reverse transcription was performed using the Quantitect Reverse Transcription kit (Qiagen, Boston, MA, USA), according to the manufacturer's protocol, followed by qPCR using the DyNAmo ColorFlash SYBR Green qPCR kit (Thermo Fisher Scientific, Waltham, MA, USA) and the LightCycler 480 Detection System (Roche). The samples were transferred to the thermal cycler, and DNA was amplified using the following thermocycling conditions: 40 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 10 s and extension at 72°C for 30 s. Glyceraldehyde 3-phosphate dehydrogenase served as an internal control.
The primers used for IL-10 were as follows: forward 5′-CGAGA TCTCCGAGATGCC-3′ and reverse 5′-AGTTCACATGCGCCTTGA-3′.
Enzyme-linked immunosorbent assay (ELISA)
Plasma IL-10 level in the cGVHD patients and cell supernatant IL-10 levels were measured before and after MSCs treatment using a commercially available ELISA system, according to the manufacturer's recommended procedures (R&D Systems, Minneapolis, MN, USA).
Flow cytometric analysis and cell sorting
The flow cytometric analysis of cell phenotypes and cell sorting were performed according to routine laboratory methods, as described in the Supplementary Information.
Intracellular cytokine staining
Sorted CD19+ B cells from healthy donors and cGVHD patients were resuspended in RPMI-1640 medium. After 5 h of stimulation with Brefeldin A (BFA, 10 μg/ml; Sigma, St Louis, MO, USA), phorbol-12-myristate-13-acetate (PMA, 50 ng/ml; Sigma) and ionomycin (1 μg/ml; Sigma), the cells were fixed, permeabilized and stained for cell surface CD3, CD19 and CD5 and cytoplasmic IL-10 according to the manufacturer's instructions. The stained cells were then analyzed by flow cytometry.
Sorted CD5+CD19+ B cells from healthy donors or cGVHD patients were cultured in duplicate wells with or without lipopolysaccharide (LPS; 10 μg/ml) for 24 h. Purified CD3+ T cells were divided into three groups and cultured in 96-well plates. One group was cultured alone, another group was cultured with inactivated B cells (at a ratio of 2:1) and the last group was cultured with LPS-activated B cells (at a ratio of 2:1). CD3+ T cells were stimulated with an anti-CD3 monoclonal antibody (0.2 μg/ml, BD Biosciences Pharmingen, Franklin Lakes, NJ, USA) for 48 h, and Brefeldin A (10 μg/ml; Sigma), phorbol-12-myristate-13-acetate (50 ng/ml; Sigma) and ionomycin (1 μg/ml; Sigma) were added 5 h before the end of the culture period. The cells were stained to detect cell surface CD19 and CD3 and cytoplasmic tumor necrosis factor (TNF)-α and then analyzed by flow cytometry. In the blocking experiments, the cultures were treated with additional 10 μg/ml anti-IL-10 monoclonal antibody (R&D Systems).
Proliferation assay and survival assay
Proliferation assay and survival assay were used to explore the effect of MSCs on CD5+ B cells, as described in the Supplementary Information.
IDO activity
Indoleamine 2, 3-dioxygenase (IDO) activity was evaluated by measuring the kynurenine and tryptophan levels using high-performance liquid chromatography, as described in the Supplementary Information.
Statistical analysis
The data obtained before and after the treatment of cGVHD patients with MSCs were compared using the Wilcoxon signed-rank test, and data from the cGVHD patients and non-GVHD patients were compared using the Wilcoxon rank-sum test. The Spearman rank test was used for correlation analysis, and a smoothing technique was used to describe the correlation between IL-10-producing CD5+ B cells and the average NIH score. The data obtained for the effect of MSCs on CD5+ B cells under different culture conditions were compared using a paired T-test. All statistical analyses were performed with the aid of SPSS Version 14.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical outcomes
In the calculation of the maximum response at the 12-month follow-up, 20 of 23 patients demonstrated an overall complete response (CR) or partial response (PR) to MSCs treatment (all except YB0190871, ZA2706001 and ZA1182533) in this study. Two PR patients (ZA186822 and ZA1866784) died of fungal pneumonia, and three CR/PR patients (YB0142290, YB0142558 and YB0106922) died of leukemia relapse within 12 months of the MSCs treatment. Hence, at the end of the follow-up period in this study, 15 patients remained alive with improvement in their clinical symptoms and liver function, and three no response (NR) cGVHD patients were alive without improvement. The risks of mortality from pulmonary infection or leukemia relapse in refractory cGVHD patients after MSCs treatment were similar to those of other refractory cGVHD patients without MSCs treatment in our hospitals. The incidences of relapse (13.0%) and mortality (21.7%) were not significantly different from those observed during treatment with other therapies (relapse, 11-15% and mortality, 22-25%). 30 Most patients' overall conditions improved after MSCs treatment, and the symptoms in those who survived were significantly alleviated, especially for the skin, oral mucosa and liver. Of the 23 patients with inflamed skin, 16 displayed a CR, 4 displayed a PR and 3 displayed a minor PR. Of the 18 patients with symptoms affecting the oral mucosa, 13 displayed a CR, 3 displayed a PR, 1 displayed a minor PR and 1 displayed NR. Of the 15 patients with impaired liver function, 13 displayed a CR, 1 displayed a PR and 1 displayed NR. The responses of the cGVHD patients varied individually; some patients showed obvious improvement after the first MSCs infusion, whereas others improved after later infusions. In most of the patients who achieved either CR or PR, the best therapeutic effects were observed 3 months after the first MSCs infusion. The clinical outcomes at 3 and 12 months after the treatment are summarized in Table 2 .
The frequency of CD5+ B cells increased in cGVHD patients after MSCs treatment Based on the best clinical improvement shown at 3 months after the first MSCs infusion, we designated this time point as the posttreatment time point. In this study, we analyzed the changes in peripheral B-cell sub-populations in pre-and post-treatment cGVHD specimens and compared them with those of non-GVHD patients (non-GVHD patients were designated as patients who never suffered from aGVHD or cGVHD after HSCT and never received a MSCs infusion). The clinical characteristics of the non-GVHD patients were summarized in Table 1 . We focused on the changes in the CR/PR cGVHD patients because the statistical analysis of NR patients was limited because of the small number (n = 3).
In this study, we did not detect any striking changes in the T-cell subsets of the CR/PR cGVHD patients after MSCs treatment except the increase in the CD8+ T-cell number (Supplementary Figure S3 ), but significant changes in the B cells were observed. Compared with the pre-treatment, although the post-treatment CR/PR cGVHD patients exhibited a decrease in B-cell frequency (Figure 1a ), the frequency of CD5+ B cells within the B-cell population was markedly increased (Figure 1b ). However, the frequencies of CD5+ B cells in both pre-and post-treatment CR/PR cGVHD patients were significantly lower than that of the non-GVHD patients (Figure 1b) , and the frequency of CD5-B cells was significantly higher than that of the non-GVHD patients (Figure 1c ).
After the MSCs treatment, the absolute number of CD5+ B cell in cGVHD patients was also increased but was still lower than that of the non-GVHD patients (Supplementary Figure S4) . Taken together, the clinical improvement was accompanied by an increase in CD5+ B cells in the CR/PR cGVHD patients.
Higher frequency of CD5+IL-10+ B cells in CR/PR cGVHD patients after MSCs treatment A detailed analysis of the CD5+ B cells was conducted in cGVHD patients who received the MSCs treatment. As shown for a representative patient in Figure 2 , the frequency of IL-10producing CD5+ B cells (CD5+IL-10+ B cells) among the CD19+ B cells was significantly increased in the post-treatment CR/PR cGVHD patients (Figure 2b ), whereas no change was observed in the NR patients (Supplementary Figure S5) .
We further analyzed the correlation between the frequency of CD5+IL-10+ B cells and the average NIH score of the cGVHD patients. As shown in Figure 2c , the frequency of CD5+IL-10+ B cells was inversely correlated with the average NIH score of the CR/PR cGVHD patients (r = -0.66, P o 0.01), but there was no evident relationship in the NR cGVHD patients (Supplementary Figure S5C ). We also observed that the NIH scores of each organ were inversely correlated with the frequency of CD5+IL-10+ B cells in the CR/PR cGVHD patients (Supplementary Figure S6A) . As a result of the small number of NR patients (n = 3), the correlation between the frequency of CD5+ IL-10+ B cells and the NIH scores in the NR cGVHD patients could not be analyzed (Supplementary Figure S6B) . These results suggested that CD5+IL-10+ B cells reduce the NIH scores of the CR/PR cGVHD patients and that the MSCs may exert their curative effect by enhancing the frequency of CD5+IL-10+ B cells.
To further investigate the effects of the MSCs treatment on IL-10 production in CD5+ B cells, isolated CD5+ B cells from pre-and post-treatment cGVHD patients were cultured for 72 h, and the concentration of IL-10 in the supernatant was measured by ELISA. As shown in Supplementary Figure S7 , the MSCs treatment significantly increased IL-10 expression in CD5+ B cells, and these results were further confirmed by quantitative reverse transcription -PCR analysis (Figure 2d ). After the MSCs treatment, the plasma IL-10 level in the cGVHD patients was also significantly higher than that in the pre-treatment cGVHD patients (Figure 2e ).
We then characterized the surface phenotypes of CD5+ B cells from cGVHD patients with the expression levels of a panel of markers, including CD19, CD5, CD1d, CD11b, CD23, CD24, CD25, CD27, CD38, CD80, CD86 and CD127. These markers have been used to identify regulatory B cells (Bregs) in previous studies. [31] [32] [33] The results showed that MSCs treatment increased the frequency of CD86+CD5+ B cells (P o 0.01; Supplementary Figure S8) , and upregulated the CD86 mean fluorescence intensity (P o 0.05; Supplementary Figure S9 ), but no obvious differences were observed for other molecules on the CD5+ B cells when posttreatment GVHD patients were compared with pre-treatment patients or non-GVHD patients (Supplementary Figure S8 ). CD86 is an activation marker for B cells, and Breg cells express high levels of CD86. 34, 35 
CD5+ B cells are potent regulators of T-cell responses To determine whether CD5+ B cells have immunosuppressive effects on T cells in vitro, we next explored the effects of CD5+ B cells on CD3+ T-cell proliferation and inflammatory cytokine production in both healthy donors and cGVHD patients.
Using a CD5+ B cell/CD3+ T-cell co-culture system, the inhibitory function of CD5+ B cells was obvious at B:T ratios of 1:1 and 1:2 (Supplementary Figure S10) . Therefore, we co-cultured CD5+ B cells/CD3+ T cells and CD5-B cells/CD3+ T cells from healthy donors at a 1:2 ratio and found that the addition of resting CD5+ B cells did not decrease the percentage of TNF-α-producing T cells (CD3+TNF-α+ T cells) within the total T-cell pool (Figure 3a ). CD5+ B cells were only able to significantly reduce the percentage of CD3+TNF-α+ T cells after activation with LPS, and this inhibitory effect was abolished by the addition of anti-IL-10 neutralizing monoclonal antibody (Figure 3a ). However, neither activated CD5-B cells nor resting CD5-B cells from healthy donors could affect the TNF-α production in CD3+ T cells (Supplementary Figure S11A) .
We then observed the effects of CD5+ B cells and CD5-B cells on the function of CD3+ T cells from cGVHD patients. As shown in Figure 3b , the presence of resting CD5+ B cells obviously decreased the number of CD3+TNF-α+ T cells, and this effect was partially reversed by the addition of anti-IL-10 neutralizing monoclonal antibody (Figure 3b ). However, CD5+ B cells from cGVHD patients activated by LPS lost their inhibitory effects on TNF-α production by CD3+ T cells (Figure 3b) . Similarly, neither activated CD5-B cells nor resting CD5-B cells from cGVHD patients could regulate the TNF-α production in CD3+ T cells (Supplementary Figure S11B) .
To further determine whether IL-10 was involved in the regulatory effect of CD5+ B cells, the production of IL-10 by CD5+ B cells was detected by ELISA and ELISPOT. After LPS stimulation, an obvious increase in IL-10 production in CD5+ B cells from healthy donors was detected, whereas significantly decreased IL-10 production in CD5+ B cells from cGVHD patients was observed (Supplementary Figure S12) .
Next, we explored the effect of CD5+ or CD5-B cells on T-cell proliferation and found that the proliferation of CD3+ T cells from healthy donors or cGVHD patients was not inhibited by either CD5+ B cells (Figures 3c and d) Figures S11C and D) . 
or CD5-B cells (Supplementary
MSCs increase the frequency of CD5+ IL-10+ B cells in vitro
To determine the effects of MSCs on CD5+ B cells, CD19+ B cells from cGVHD patients were isolated and cultured either alone or with MSCs (2:1) for 5 days. After 3 days of co-culture with MSCs, the frequency of CD5+IL-10+ B cells in CD19+ B cells from the cGVHD patients increased from 3.71 ± 0.19 to 6.02 ± 0.21% (P o 0.01) and reached 8.39 ± 0.32% after 5 days of co-culture (P o 0.01; Figure 4a ). However, the frequency of CD5+IL-10+ B cells in CD19+ B cells from the cGVHD patients gradually decreased at days 3 and 5 without MSCs (Figure 4a ). The frequencies of CD5+IL-10+ B cells in CD19+ B cells from healthy donors gradually increased in the presence or absence of MSCs over the culture period, but those frequencies co-cultured with MSCs were much higher than those without MSCs (Figure 4b ). Further analysis showed that the frequencies of IL-10-producing B cells in CD5+ B cells from cGVHD patients gradually decreased in the absence of MSCs, but remained almost constant in the presence of MSCs (Supplementary Figure S13A) . In the healthy donors group, the frequencies of IL-10-producing B cells in CD5+ B cells gradually increased after co-culture with MSCs, but did not change without MSCs (Supplementary Figure S13B) .
MSCs influence the proliferation and survival of CD5+ B cells
We next assessed the effects of MSCs on the survival of CD5+ B cells and found that the survival rate of CD5+ B cells from the cGVHD patients after 96 h was much lower in culture alone than in the presence of MSCs (Figure 5a) . MSCs also increased the survival rate of CD5-B cells, but the efficiency was much lower than their effect on CD5+ B cells (Figure 5a ). The information in Figure 4 also implied that MSCs may prefer to support the survival of CD5+ B cells, as the frequencies of CD5+ B cells from both cGVHD patients and healthy donors were gradually increased after co-culture with MSCs.
In addition, we explored the effect of MSCs on CD5+ B-cell proliferation and IL-10 production. After LPS stimulation for 96 h, CD5+ B cells from the cGVHD patients exhibited a much greater proliferative capacity in the presence of MSCs than in the absence of MSCs (Figure 5b ). CD5-B cells presented the same tendency, but the efficiency was much lower than that of the CD5+ B cells co-cultured with MSCs (Figure 5b) .
Furthermore, the frequency of CD5+IL10+ B cells was significantly higher when B cells were co-cultured with MSCs than without MSCs (Figure 5c ). After co-culture with MSCs, the frequency of IL-10-producing CD5-B cells was also increased compared with cells cultured without MSCs (Figure 5c ). Although the frequencies of IL-10-producing cells were increased in both CD5+ B cells and CD5-B cells during co-culture with MSCs, the increase in IL-10-producing CD5+ B cells was markedly greater than the increase in IL-10-producing CD5-B cells (Figure 5c ).
MSCs influence the proliferation and survival of CD5+ B cells via the IDO pathway in vitro
To gain further insight into the mechanism of the MSC-mediated proliferation, survival and function of CD5+ B cells, we tested several potential mediators using monoclonal neutralizing antibodies specific for IL-6 and IL-10 or specific inhibitors for IDO (DL-1MT) or COX-2 (NS398). Among these targets, only DL-1MT, a specific IDO inhibitor, could partially reverse the MSC-mediated effects on CD5+ B-cell survival (Figures 6a and c) and proliferation (Figures 6b and d) . None of the inhibitors or antibodies tested had any obvious effects on the MSC-mediated upregulation of IL-10 production by CD5+ B cells (Figure 6e ).
To further confirm whether the immunosuppressive effect of MSCs is due to IDO, we measured the IDO activity through the ratio of kynurenine to tryptophan in the supernatants from the CD5+ B cells/MSCs or CD5-B cells/MSCs co-culture systems. Figure S14A , IDO activity in the CD5+ B cells/MSCs co-culture was significantly higher than that in the CD5-B cells/MSCs co-culture. Western blot analysis also showed that IDO expression could only be detected in interferon (IFN)-γpriming MSCs and MSCs co-cultured with CD5+ B cells, whereas no band was observed in the MSCs co-cultured with CD5-B cells (Supplementary Figure S14B) .
As shown in Supplementary
To further confirm the role of IDO, we investigated the effect on the survival and proliferation of CD5+ B cells through the inhibition of IDO or ablation of IDO expression in MSCs. As shown in Supplementary Figures S15 and S16 , although L-1MT and D-1MT could partially reverse the MSC-mediated effect on CD5+ B cells, L-1MT inhibited the B cells to a greater extent than D-1MT. In contrast, neither L-1MT nor D-1MT influenced CD5-B cells cocultured with MSCs ( Supplementary Figures S15 and S16) . The small interfering RNA-mediated blocking of IDO (knock-down efficiency of 480% as measured by quantitative reverse transcription-PCR, data not shown) in MSCs also partially reversed the MSC-mediated effects on CD5+ B-cell survival and proliferation without obviously affecting the CD5-B cells (Supplementary Figure S15 and S16).
As IDO expression in MSCs is well known to require priming by IFN-γ, 36 we evaluated IFN-γ production in both CD5+ B cells and CD5-B cells stimulated by LPS for 72 h. As shown in Supplementary Figures S14C, the frequency of IFN-γ production in CD5+ B cells was much higher than in CD5-B cells. Previous studies demonstrated that both mouse and human B cells produced IFN-γ under different conditions. 37, 38 Altogether, these data suggested that IDO was involved in the MSC-mediated effects on CD5+ B cells.
DISCUSSION
cGVHD is an immune system-mediated disease that is thought to be caused by complex interactions between the adaptive immune cells of the donor and the recipient. Le Blanc and colleagues have previously assessed the immune alterations after MSCs infusion in aGVHD patients and found that the infusion of MSCs was associated with increased levels of T regulatory cells and IL-10+ T cells as well as reduced Th17 cells. 39 In this study, we observed that the clinical improvement of cGVHD was accompanied by a significant increase in CD5+ B cells in CR/PR cGVHD patients, whereas no striking changes were observed in the frequency of T lymphocyte subsets. This difference was quite likely caused by the difference in the study subjects; Le Blanc's group focused on aGVHD patients, and our study focused on cGVHD patients. It is well known that aGVHD and cGVHD involve distinct pathological processes; aGVHD is thought to be mainly a Th1/Th17-driven process and to have strong inflammatory components, whereas cGVHD displays more autoimmune and fibrotic features. 23 Previous studies have shown that patients with cGVHD had fewer CD5+ B cells than non-GVHD patients. 26 Moreover, an increase in CD5+ B cells is thought to represent the first wave of circulating cells following bone marrow transplantation, and CD5+ B-cell levels exhibit a more rapid recovery in non-GVHD patients. 25 Recently, van Dorp et al. reported that an elevation in the CD5 expression on B cells was found in responding patients in a phase II rituximab treatment study of 20 patients with steroid-refractory cGVHD. 40 B cells have been identified as potent regulators of T cells through their ability to express IL-10. 20 Bregs exert their suppressive properties in different ways, including Th1 and Th17 differentiation inhibition, regulatory T-cell induction, and also a direct inhibitory effect on antigen presentation by dendritic cells. 41 There were no validated phenotypic markers of Bregs until Tedder and colleagues identified regulatory CD5+ B cells based on IL-10 expression. 32 The regulatory capacity of unique IL-10producing CD5+ Breg cells has been shown in a variety of mouse models of allergic and autoimmune diseases. 24, 42 In this study, we also observed a remarkable increase in the frequency of CD5+IL-10+ B cells in the CR/PR cGVHD patients after MSCs treatment. Moreover, all CD5+ B cells from both healthy donors and cGVHD patients had an IL-10-dependent immunomodulatory effect on inflammatory cytokine (TNF-α) production in CD3+ T cells, which has a pathogenic role in cGVHD development. 43, 44 Le Huu et al. 45 reported that the early adoptive transfer of CD1d hi CD5+ B10 cells ameliorated the severity of a murine sclerodermatous cGVHD model by suppressing T-cell inflammatory cytokine production. However, these CD5+ B10 cells could not inhibit cGVHD T-cell proliferation, which was similar to our result. Most recently, Weber et al. 46 demonstrated that host Figure 5 . MSCs improve B-cell survival and promote the proliferation and IL-10 production of B cells. In the presence of MSCs, the survival rate (a) and proliferation (b) of CD5+ B cells were much higher than those of CD5-B cells in the cGVHD patients and also much higher than those in the absence of MSCs. In the presence of MSCs, the IL-10 production of CD5+ B cells was much higher than that of CD5-B cells in the cGVHD patients and also much higher than those in the absence of MSCs (c). The results are representative of three independent experiments. Significant differences are indicated as follows: *P o0.05 and **Po0.01. and donor B-cell-derived IL-10 provides a unique mechanism for the suppression of GVHD.
At the same time, we found that the behavior of CD5+ cells from healthy donors and cGVHD patients is different. CD5+ B cells from healthy donors have to be activated by LPS ex vivo before they have regulatory functions, whereas those from cGVHD patients possess regulatory functions without activation. In contrast, the LPS activation of CD5+ B cells from cGVHD patients ex vivo causes the cells to lose their regulatory function. Thus, the response of CD5+ B cells to LPS activation appears to be different. After the stimulation with LPS, most of the CD5+ B cells from cGVHD patients decreased their IL-10-producing ability. We speculated that different microenvironments affect the response of CD5+ B cells to LPS activation. Many of the clinical, histological and serological manifestations of cGVHD resemble autoimmune disease, 23 which implies that CD5+ B cells may be pre-activated in the inflammatory microenvironment. After the stimulation with LPS in vitro, pre-activated CD5+ B cells may lose their ability to produce IL-10. A previous study also showed significantly more unstimulated B cells that spontaneously produce IL-10 in systemic lupus erythematosus patients compared with controls. 47 After 24 h of phorbol-12-myristate-13-acetate/ionomycin stimulation, a significant increase in the percentage of B cells producing IL-10 was observed in healthy donors, whereas a reduction in the percentage of IL-10-producing B cells was observed in systemic lupus erythematosus patients. 47 Previous studies have had contradictory results regarding the role of MSCs in B-cell proliferation, with some studies demonstrating that MSCs could sustain B-cell proliferation [48] [49] [50] but others reporting that MSCs inhibit B-cell proliferation. 51 Herein, we have demonstrated that MSCs increase CD5+ Bregs by promoting proliferation and survival of CD5+ B cells from CR/ PR cGVHD patients and healthy donors. Mechanistically, the inhibition of the IDO pathway partially reversed the MSCmediated CD5+ B cells survival and proliferation without affecting IL-10 production. However, blocking other molecules, including COX-2/PGE2, IL-6 and IL-10, which are involved in the immunomodulatory functions of MSCs, 52 did not abrogate the role of MSCs in increasing CD5+ B cells and IL-10 production, indicating that some as yet unidentified mediators may exist.
In summary, the data suggest that MSCs treatment likely improves symptoms in cGVHD patients by increasing CD5+ B cells and IL-10 production in CD5+ B cells. We have demonstrated for the first time, to the best of our knowledge, that MSCs could increase the frequency and function of CD5+ B cells by promoting the proliferation and survival of CD5+ B cells and stimulating the production of the anti-inflammatory cytokine IL-10 by CD5+ B cells. Despite the limited sample size in this study, these findings have provided new hints for elucidating the therapeutic mechanisms of MSCs treatment for cGVHD, which may be used to improve their therapeutic impact.
